Anika Therapeutics, Inc.

Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

아니카 테라퓨틱스(Anika Therapeutics, Inc.)는 관절 보존 전문 기업으로, 미국, 유럽 및 전 세계적으로 조기 개입 정형외과 분야에 주력하고 있습니다. 이 회사는 골관절염(OA) 통증 관리 제품 및 서비스를 제공합니다. 여기에는 OA 증상으로 인한 통증 완화에 사용되는 1회 및 다회 주사형 HA 점액 보충제 제품인 Monovisc 및 Orthovisc, 그리고 비마약성 1회 주사형 OA 통증 관리 제품인 Cingal이 포함됩니다. 재생 솔루션으로는 뼈 및 힘줄 고정 구성 요소와 관절경 전달 기구를 갖춘 HA 기반 스캐폴드, 단일 단계 연